

Please type a plus sign inside the box.

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/748,089
		Filing Date	December 29, 2003
		First Named Inventor	Andrei W. KONRADI
		Group Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	10	Attorney Docket Number	42837-2001021

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Transmittal Form (1 pg.) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (4 pgs.) <input checked="" type="checkbox"/> Information Disclosure Citation PTO-Form 1449 w/ 115 documents listed, but not enclosed (5 pgs.) <input type="checkbox"/> Response to Notice to File Missing Parts <input type="checkbox"/> Copy of Response to Notice to File Missing Parts	<input type="checkbox"/> Assignment and Recordation Cover Page <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)
1. Return postcard Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	SWISS LAW GROUP Lorna L. Tanner (Reg. No. 50,782)	38706
Signature		
Date	February 11, 2004	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as 1st Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Dated: 2.11.04

Signature:
Angela D. Nijim



I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope with sufficient postage affixed and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 2.11.04

Name: *Angela D. Yogi*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Andrei W. KONRADI, et al.	Confirmation No.:	Unknown
Serial No.:	10/748,089	Art Unit:	Not Yet Assigned
Filed:	December 29, 2003	Examiner:	Not Yet Assigned
For:	HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Attorney Docket No.:	42837-2001021

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:
 - 1a. A PTO-Form 1449 listing all patents, publications, applications, or other information submitted for consideration by the office.
 - 1b. A legible copy of :
 - Each U.S. patent application publication and U.S. and foreign patent;
 - Each publication or that portion which caused it to be listed on the PTO-1449;
 - For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;

- all other information or portion which caused it to be listed on the PTO-1449.
- 1c. An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.
- 1d. Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
- 2. This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
 - Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
 - Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - Before the mailing of the first Office action on the merits;
 - Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- 3. This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.
 - 3a. The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
 - 3b. The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
 - enclosed
 - to be charged to Swiss Law Group LLP Deposit Account No. 50-2859.
- 4. This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

 - enclosed.
 - to be charged to Swiss Law Group LLP Deposit Account No. 50-2859.
- 5. Certification Statement (applicable if Item 3a or Item 4 is checked)
 - 5a. In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not

Application No. 10/748,089
Attorney Docket No. 42837-2001021

more than three months prior to the filing of this Information Disclosure Statement.

5b. Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

5c. Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

6. This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

6a. A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.

6b. Copies of publications listed on Form PTO-1449 from prior application Serial No. 10/241,442, filed on September 20,2002, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).

6c. Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.

7. This is a Supplemental Information Disclosure Statement.

7a. This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .

8. In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

8a. satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.

8b. set forth in the application.

8c. enclosed as an attachment hereto.

9. The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Swiss Law Group Deposit Account No. 50-2859.

Application No. 10/748,089
Attorney Docket No. 42837-2001021

10. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).


Respectfully submitted,

Date: **February 11, 2004**



Lorna L. Tanner
Reg. No. 50,782
SWISS LAW GROUP
Bldg. 3, Palo Alto Square
3000 El Camino Real, Ste. 100
Palo Alto, California 94306
(650) 856-3704

Application No. 10/748,089
Attorney Docket No. 42837-2001021

PTO-Form 1449					ATTY DOCKET NO. 42837-2001021	APPLICATION NO 10/748,089	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					APPLICANT Andrei W. KONRADI, et al.		
					FILING DATE December 29, 2003	GROUP Not yet assigned	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
1.		4,018,913	04/19/77	Okamoto, et al. (equiv to DE 2655636)			
2.		4,018,915	04/19/77	Okamoto, et al. (equiv to DE 2655636)			
3.		4,036,955	07/10/77	Okamoto, et al. (equiv to DE 2655636)			
4.		4,041,156	08/09/77	Okamoto, et al. (equiv to DE 2655636)			
5.		4,046,876	09/06/77	Okamoto, et al. (equiv to DE 2655636)			
6.		4,055,651	10/25/77	Okamoto, et al. (equiv to DE 2655636)			
7.		4,055,636	10/25/77	Okamoto, et al. (equiv to DE 2655636)			
8.		4,070,457	01/24/78	Okamoto, et al. (equiv to DE 2655636)			
9.		4,073,914	02/14/78	Kikumoto, et al. (equiv to DE 2655636)			
10.		4,085,057	04/18/78	Masuda, et al.			
11.		4,096,255	06/20/78	Kikumoto, et al. (equiv to DE 2655636)			
12.		4,104,392	08/01/78	Okamoto, et al. (equiv to DE 2655636)			
13.		4,438,122	03/20/84	Holmwood, et al.			
14.		4,505,910	03/19/85	Bagli			
15.		4,518,600	05/21/85	Holmwood, et al.			
16.		4,544,402	10/01/85	Schnurbusch, et al.			
17.		4,559,345	12/17/85	Gomarasca, et al.			
18.		4,672,065	06/09/87	Spatz			
19.		4,908,368	03/13/90	Murase, et al.			
20.		4,959,364	09/25/90	Mueller, et al.			
21.		4,992,439	02/12/91	Meanwell			
22.		5,030,644	07/09/91	Baldwin, et al.			
23.		5,120,734	06/09/92	Klausener, et al.			
24.		5,238,934	08/24/93	Knuppel, et al.			
25.		5,278,184	01/11/94	Artico, et al.			
26.		5,510,332	04/23/96	Kogan, et al.			
27.		5,580,868	12/03/96	Lunkenheimer, et al.			
28.		5,770,573	06/23/98	Arrhenius, et al.			
29.		5,814,643	09/29/98	Duggan, et al.			

ATTY DOCKET NO.


42837-2001021

APPLICATION NO

10/748,089

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



APPLICANT

Andrei W. KONRADI, et al.

FILING DATE

December 29, 2003

GROUP

Not yet assigned

Sheet 2 of 5


30.	5,861,429	01/19/99	Sato, et al.			
31.	5,925,644	07/20/99	Jakobi, et al.			
32.	5,942,504	08/24/99	Grobelny			
33.	5,955,491	09/21/99	Sohda, et al.			
34.	5,962,479	10/05/99	Chen			
35.	5,972,946	10/26/99	Murata, et al.			
36.	6,005,117	12/21/99	Wehner, et al.			
37.	2002/0052375	05/02/02	Konradi, et al.			
38.	2002/0055509	05/09/02	Konradi, et al.			
39.	2003/0144328	07/31/03	Konradi, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
40.	2,241,149	07/03/77	Canada (equiv to DE 19548709)						
41.	2,259,224	01/08/78	Canada (equiv to DE 19654483)						
42.	0 116 494	08/1984	Europe						
43.	0 147 211	07/03/93	Europe						
44.	0 288 176	10/26/88	Europe						
45.	0 330 506 A2	08/30/89	Europe						
46.	0 330 506 A3	08/30/89	Europe						
47.	0 526 348	02/03/93	Europe						
48.	0 535 521	04/07/93	Europe						
49.	19548709	07/03/97	Germany (equiv to CA 2,241,149)						
50.	19536891	04/1997	Germany						
51.	19654483	01/02/98	Germany (equiv to CA 2,259,224)						
52.	19713000	10/01/98	Germany (Abstract)						
53.	2655636	06/23/77	Germany (US equiv are all Okamoto and Kikumoto US patents listed above)						
54.	1500063	02/08/78	Great Britain (equiv to HU 169926)						
55.	169926	09/28/76	Hungary (equiv to GB 150063)						
56.	59212480	12/1984	Japan (Abstract)						
57.	92/16549	10/01/92	WIPO						
58.	93/12809	07/08/93	WIPO						
59.	96/01644	01/25/96	WIPO						

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY DOCKET NO.

42837-2001021

APPLICATION NO

10/748,089

APPLICANT

Andrei W. KONRADI, et al.

FILING DATE

December 29, 2003

GROUP

Not yet assigned

Sheet 3 of 5


	60.	96/22966	08/01/96	WIPO				
	61.	96/32383	04/1997	WIPO				
	62.	97/23451	07/03/97	WIPO				
	63.	98/00395	01/08/98	WIPO				
	64.	98/33783	12/03/98	WIPO				
	65.	98/53814	12/03/98	WIPO (Abstract)				
	66.	98/53817	08/06/98	WIPO				
	67.	99/06431	02/11/99	WIPO				
	68.	99/06432	02/11/99	WIPO				
	69.	99/06433	02/11/99	WIPO				
	70.	99/06390	02/11/99	WIPO				
	71.	99/06391	02/11/99	WIPO				
	72.	99/10312	03/04/99	WIPO				
	73.	99/10313	03/04/99	WIPO				
	74.	99/37605	07/29/99	WIPO				
	75.	99/37618	07/29/99	WIPO				
	76.	99/52898	10/21/99	WIPO				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	77.	Abraham, et al. "Alpha4-Integrins Mediate Antigen-Induced Late Bronchial Responses and Prolongs Airway Hyperresponsiveness in Sheep," <i>J. Clin. Invest.</i> 93: 776-787 (1994).
	78.	Advani, S.B., et al. "Potential Antineoplastic Agents: N-(1-Benzoxazolyl)amino Acid Esters," <i>J. Pharm. Sci.</i> 57(10): 1693-1696 (1968).
	79.	Bao, et al. "Correlation of VLA-4 Integrin Expression with Metastatic Potential in Various Human Tumor Cell Lines," <i>Diff.</i> 52: 239-246 (1993).
	80.	Baron, et al. "Surface Expression of $\alpha 4$ Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma," <i>J. Exp. Med.</i> 177: 57-68 (1993).
	81.	Baron, et al. "The Pathogenesis of Adoptive Murine Autoimmune Diabetes Requires an Interaction between $\alpha 4$ -Integrins and Vascular Cell Adhesion Molecule-1," <i>J. Clin. Invest.</i> 93: 1700-1708 (1994).
	82.	Burkly, et al. "Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigen-4 Integrin," <i>Diabetes</i> 43: 529-534 (1994).
	83.	Cybulsky, et al. "Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule during Atherogenesis," <i>Science</i> 251: 788-791 (1991).
	84.	Elices, et al. "Expression and Functional Significance of Alternatively Spliced CS1 Fibronectin in Rheumatoid Arthritis Microvasculature," <i>J. Clin. Invest.</i> 93: 405-416 (1994).
	85.	Elices, et al. "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site," <i>Cell</i> 60: 577-584 (1990).
	86.	Gordeev, M.F., et al. "Combinatorial Approaches to Pharmacophoric Heterocycles: A Solid-Phase Synthesis of 3,1-Benzoxazine-4-ones," <i>Biotech. And Bioengineering</i> 61(1): 13-16 (1998).
	87.	Hamann, et al. "Role of $\alpha 4$ -Integrins in Lymphocyte Homing to Mucosal Tissues <i>In Vivo</i> ," <i>J. Immunol.</i> 152: 3283-3292 (1994).
	88.	Henke, B.R., et al. "N-(2-Benzoylphenyl)-L-tyrosine: Aryl Agonists. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents," <i>J. Med. Chem.</i> 41(25): 5020-5036 (1998).

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY DOCKET NO.

42837-2001021

APPLICATION NO

10/748,089

APPLICANT

Andrei W. KONRADI, et al.

FILING DATE

December 29, 2003

GROUP

Not yet assigned

Sheet 4 of 5

	89.	Hladon, B., et al. "In Vitro cytostatic activity of some amino acid 4-N-subsituted cytosines," <i>Arch. Immunol. Ther. Exp.</i> 40(2): 145-150 (1992) (Abstract)
	90.	Hoffman, S., et al. "N-Pyrimidinylamino acids, III. N-(oxopyrimidinyl) derivatives of neutral amino acids, <i>Z. Chem.</i> 12(1): 21-22 (1972). CODEN: ZEACEAL. (Abstract).
	91.	Jaeger, et al. <i>Chem. Berichte.</i> 101(8): 2762-2770 (1968). Chem. Abstract 69: 676 Kawaguchi, et al. "VLA-4 Molecules on Tumor Cells Initiate an Adhesive Interaction with VCAM-1 Molecules on Endothelial Cell Surface," <i>Jap. J. Canc. Res.</i> 83: 1304-1316 (1992).
	92.	Lauri, et al. "Decreased Adhesion to Endothelial Cells and Matrix of H-2K ^b Gene Transfected Tumor Cells," <i>Br. J. Canc.</i> 68: 862-867 (1993).
	93.	Lazer, E. S., et al. "Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action," <i>J. Med. Chem.</i> 37(7): 913-923 (1994).
	94.	Li, et al. "An Atherogenic Diet Rapidly Induces VCAM-1, a Cytokine-Regulatable Mononuclear Leukocyte Adhesion Molecule in Rabbit Aortic Endothelium," <i>Arterioscler. Thromb.</i> 13: 197-204 (1993).
	95.	Ma, D., et al. "Accelerating Effect Induced by the Structure of α -Amino Acid in the Copper Catalyzed Coupling Reaction of Aryl Halides with α -Amino Acids. Synthesis of Benzolactam-V8," <i>J. Am. Chem. Soc.</i> 120(48): 12459-12467 (1998).
	96.	Marr-Leisy, et al. <i>Colloid and Polymer Sc.</i> 263(10): 791-798 (1985). Chem. Abstract 105: 97885
	97.	Mulligan, et al. "Role of $\beta 1$, $\beta 1$ Integrins and ICAM-1 in Lung Injury after Deposition of IgG and IgA Immune Complexes," <i>Immunology</i> 150: 2407-2417 (1993).
	98.	Ohta, et al. <i>Heterocycles</i> 31(9): 1655-1662 (1990). Chem. Abstract 114: 101454-1991:101454
	99.	Ohta, et al. <i>Chem. & Pharmaceutical Bulletin</i> 27(12): 2980-2987 (1979). Chem. Abstract 93: 46584-1980: 446584
	100.	Okahara, et al. "Involvement of Very Late Activation Antigen 4 (VLA-4) and Vascular Cell Adhesion Molecule 1 (VCAM-1) in Tumor Necrosis Factor α Enhancement of Experimental Metastasis," <i>Can. Res.</i> 54: 3233-3236 (1994).
	101.	Osborn. "Leukocyte Adhesion to Endothelium in Inflammation," <i>Cell</i> 62: 3-6 (1990).
	102.	Paavonen, et al. " <i>In Vivo</i> Evidence of the Role of $\alpha 4\beta 1$ -VCAM-1 Interaction in Sarcoma, but not in Carcinoma Extravasation," <i>Int. J. Can.</i> 58: 298-302 (1994).
	103.	Paul, et al. "Monoclonal Antibodies Against LFA-1 and VLA-4 Inhibit Graft Vasculitis in Rat Cardiac Allografts," <i>Transpl. Proceed.</i> 25: 813-814 (1993).
	104.	Postigo, et al. "Increased Binding of Synovial T-Lymphocytes from Rheumatoid Arthritis to Endothelial-Leukocyte Adhesion Molecule-1 (ELAN-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1)," <i>J. Clin. Invest.</i> 89: 1445-1452 (1992).
	105.	Pretolani, et al. "Antibody to Very Late Activation Antigen 4 Prevents Antigen-induced Bronchial Hyperreactivity and Cellular Infiltration in the Guinea Pig Airways," <i>J. Exp. Med.</i> 180: 795-805 (1994).
	106.	Sasseville, et al. "Monocyte Adhesion to Endothelium in Simian Immunodeficiency Virus-Induced AIDS Encephalitis is Mediated by Vascular Cell Adhesion Molecule-1/ $\alpha 4\beta 1$ Integrin Interactions," <i>Am. J. Path.</i> 144: 27 (1994).
	107.	Schadendorf, et al. "Tumor Progression and Metastatic Behavior <i>In Vivo</i> Correlates with Integrin Expression in Melanocytic Tumors," <i>J. Path.</i> 170: 429-434 (1993).
	108.	Simchowitz, et al. <i>J. Biol. Chem.</i> 265(23): 13457-13463-1990:530558
	109.	Springer, et al. "Adhesion Receptors of the Immune System," <i>Nature.</i> 346: 425-434 (1990).
	110.	Teranishi, K., et al. "Synthesis and Chemiluminescence of Coelenterazine (Ophorophorus Luciferin) Analogs," <i>Bull. Chem. Soc., Jpn.</i> 63(11): 3132-3140 (1990).
	111.	van Dinther-Janssen, et al. "Role of the CS1 Adhesion Motif of Fibronectin in T Cell Adhesion to Synovial Membrane and Peripheral Lymph Node Endothelium," <i>Annals. Rheumatic Dis.</i> 52: 672-676 (1993).
	112.	van Dinther-Janssen, et al. "The VLA-4/VCAM-1 Pathway is Involved in Lymphocyte Adhesion to Endothelium in Rheumatoid Synovium," <i>J. Immunology.</i> 147: 4207-4210 (1991).

INFORMATION DISCLOSURE CITATION
 (Use several sheets if necessary)



ATTY DOCKET NO.	APPLICATION NO
42837-2001021	10/748,089

APPLICANT
Andrei W. KONRADI, et al.

FILING DATE	GROUP
December 29, 2003	Not yet assigned

Sheet 5 of 5

	113.	Vedder, et al. "Role of Neutrophils in Generalized Reperfusion Injury Associated with Resuscitation from Shock," <i>Surgery</i> 106: 509-516 (1989).
	114.	Yang, et al. "Inhibition of Insultitis and Prevention of Diabetes in Nonobese Diabetic Mice by Blocking L-Selectin and Very Late Antigen 4 Adhesion Receptors," <i>Proc. Natl. Acad. Sci. (USA)</i> 90: 10494-10498 (1993).
	115.	Yednock, et al. "Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies Against $\alpha 4\beta 1$ Integrin," <i>Nature</i> 356: 63-66 (1992).

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.